# Dabigatran

## Pradaxa 150mg

| TAH Drug Code      | [OPR150](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OPR150)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Indicated for the prevention of venous thromboembolism (VTE) in patients at high risk of venous thrombosis undergoing major orthopedic surgery of the lower limbs. Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Treatment of acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE) in adults.                                                                                                                                                                                                                                                                                    |
| Dosing             | Prevent stroke and systemic embolism in patients with non-vavular atrial fibrillation: adult patients with a CrCl greater than 30 mL/min is 110-150 mg orally twice daily， with or without food. For prophylaxis of venous thrombosis of hip replacement surgery， starting 75mg within 1-4 hours after the operation， then 150mg once daily for 28-35 days. (for knee replacement surgery 10 days.) Treatment of acute deep vein thrombosis(DVT) and/or pulmonary embolism(PE): Adult: recommended to be treated with injectable anticoagulant for at least 5 days， then 150mg twice a day for 6 months.                                |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Known hypersensitivity to dabigatran， dabigatran etexilate， or any excipient of this product. Severe renal impairment (creatinine clearance <30 ml/min). Patients with active bleeding， bleeding disorders， or impaired hemostasis due to spontaneous or drug-induced conditions. Hepatic impairment. Organic lesions with a high risk of clinically significant bleeding， including hemorrhagic stroke within the past six months. Concomitant systemic treatment with ketoconazole， cyclosporine， or itraconazole. Patients with mechanical prosthetic heart valves. Fixed-dose combination therapy with glecaprevir/pibrentasvir. |
| Adverse Effects    | Gastrointestinal: Dyspepsia (11%; includes abdominal discomfort/pain， epigastric discomfort) GI hemorrhage (<6%)， gastritis-like symptom Hematologic: Bleeding (8% to 33%; major: <6%) Anemia (1% to 4%) hematoma (1% to 2%) hemoglobin decreased (1% to 2%) hemorrhage (postprocedural or wound: 1% to 2%) Hepatic: ALT increased (>3 x ULN: 2% to 3%) Renal: Hematuria (1%) Miscellaneous: Wound secretion (5%)， postprocedural discharge (1%)                                                                                                                                                                                         |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| More Info          | [UpToDate](https://www.uptodate.com/contents/dabigatran-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

## Pradaxa 110mg

| TAH Drug Code      | [OPRAD](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OPRAD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Indicated for the prevention of venous thromboembolism (VTE) in patients at high risk of venous thrombosis undergoing major orthopedic surgery of the lower limbs. Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Treatment of acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE) in adults.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Dosing             | Prevent stroke and systemic embolism in patients with non-vavular atrial fibrillation:adult patients with a CrCl greater than 30 mL/min is 110-150 mg orally twice daily， with or without food. For prophylaxis of venous thrombosis of hip replacement surgery， starting 75mg within 1-4 hours after the operation， then 150mg once daily for 28-35 days. (for knee replacement surgery 10 days.) Treatment of acute deep vein thrombosis(DVT) and/or pulmonary embolism(PE): Adult: recommended to be treated with injectable anticoagulant for at least 5 days， then 150mg twice a day for 6 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | Known hypersensitivity to dabigatran， dabigatran etexilate， or any excipient of this product. Severe renal impairment (creatinine clearance <30 ml/min). Patients with active bleeding， bleeding disorders， or impaired hemostasis due to spontaneous or drug-induced conditions. Presence of organic lesions with a high risk of clinically significant bleeding， including a history of hemorrhagic stroke within the past six months. Concomitant systemic treatment with ketoconazole， cyclosporine， or itraconazole. Patients with mechanical prosthetic heart valves. Fixed-dose combination therapy with glecaprevir/pibrentasvir. PRADAXA should not be used in patients with severe renal impairment (CrCl <30 mL/min); if used， it must be discontinued at least five days before major surgery. Patients with hepatic impairment or liver disease expected to have an impact on survival should not use this medication. Patients undergoing major orthopedic surgery and already receiving PRADAXA treatment should avoid initiating verapamil therapy.                                                                                  |
| Adverse Effects    | Common: Esophagitis， Gastritis， Gastroesophageal reflux disease (Atrial fibrillation， 5.5%)， Gastrointestinal hemorrhage (Adult， DVT and pulmonary embolism， 0.7-3.1%; adult， nonvalvular atrial fibrillation， 6.1% ; pediatric， 5.7%)， Gastrointestinal ulcer， Indigestion (Adult， DVT and pulmonary embolism， 4.1-7.5% ; pediatric， 5-9%)， Hemorrhage (Adult， DVT and pulmonary embolism treatment or prophylaxis， 9.7-12.3%; adult， nonvalvular atrial fibrillation， 16.6% ; pediatric， 20-22%). Serious: Myocardial infarction (DVT and pulmonary embolism， 0.1-0.66%; nonvalvular atrial fibrillation， 0.7%)， Gastrointestinal hemorrhage， Major (DVT and pulmonary embolism， 0.1-0.6%; nonvalvular atrial fibrillation， 1.6%)， Upper gastrointestinal bleeding， Hemorrhage， Major (Adult， DVT and pulmonary embolism， 0.3-2%; adult， nonvalvular atrial fibrillation， 3.3% ; pediatric， 1.4-2.3%)， Thrombosis， Anaphylaxis， Epidural hematoma， Intracranial hemorrhage (Nonvalvular atrial fibrillation， 0.3%; DVT and pulmonary embolism， 0.1%)， Traumatic spinal subdural hematoma， Hemorrhage， Alveolar. |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| More Info          | [UpToDate](https://www.uptodate.com/contents/dabigatran-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

